News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies: First Quarter 2012 Topline, Scientific Activity and Upcoming Clinical Data


5/15/2012 10:18:29 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its first quarter topline and its intense scientific activity and clinical data disclosure schedule for the coming weeks.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES